|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Prospects of Harm reduction strategy in combating the spread of HIV in Ukraine (UKR)V. V. KorolenkoO. O. Bogomolets National Medical University, Kyiv, Ukraine |
---|
Keywords: epidemiology, public health, harm reduction, HIV, IDU, patient organizations.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Introduction Bedakvilina in Ukraine: a new hope for patients with resistant forms of tuberculosis (UKR)N.À. Lytvynenko1, Î.V. Pavlova2, K.Î. Hamazyna2, E. Vaitek3, A.I. Barbova11 S² «National Institute of Phthisiology and Pulmonology named by F.G. Yanovsky NAMS of Ukraine», Kyiv, Ukraine |
---|
Keywords: Bedakvilin, new drugs, multidrug-resistant tuberculosis.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 State immunity in the comprehensive treatment of tuberculosis (unspecified location, rifampicin-resistant of lungs, chemoresistant military and multi-resistant nervous system) in combined with HIV (UKR)V. I. Petrenko1, O. V. Panasiuk1—4, G. V. Padysh1, O. B. Holub4, Ya. V. Lopatina4, L. S. Nychyporenko31 O.O. Bogomolets National Medical University, Kyiv, Ukraine |
---|
Keywords: tuberculosis, specified, unspecified, chemoresistant, complex treatment, the condition of immunity, the combination with HIV.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Treatment outcomes of multidrug-resistant tuberculosis in Kyiv Îblast (UKR)O. Aibana1, M. Bachmaha2, V. Krasiuk3, N. Rybak4, V. Shurypa6, |
---|
Keywords: Multidrug-resistant, tuberculosis, risk factors, treatment outcomes.
List of references:
1. World Health Organization. Global tuberculosis report 2016. http://www.who.int/tb/publications/global_report/en/. Accessed 20 Oct 2016.
2. World Health Organization. Tuberculosis country profiles. http://www.who.int/tb/country/data/profiles/en/. Accessed 20 Oct 2016.
3. Farley JE, Ram M, Pan W, Waldman S, Cassell GH, Chaisson RE, et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One. 2011;6(7):e20436.
4. Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000—2003. Int J Tuberc Lung Dis. 2010;14(4):413-9.
5. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J. 2009;33(5):1085-94.
6. Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb). 2012;92(5):397-403.
7. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4(9):e6914.
8. Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10(4):402-8.
9. Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, Llaro K, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008;46(12):1844-51.
10. Miller AC, Gelmanova IY, Keshavjee S, Atwood S, Yanova G, Mishustin S, et al. Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation. Int J Tuberc Lung Dis. 2012;16(7):891-6.
11. Satti H, McLaughlin MM, Hedt-Gauthier B, Atwood SS, Omotayo DB, Ntlamelle L, et al. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLoS One. 2012;7(10):e46943.
12. Palacios E, Franke M, Muñoz M, Hurtado R, Dallman R, Chalco K, et al. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis. 2012;16(3):348-54.
13. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(3):153-61.
14. Ministry of Health of Ukraine, Unified Clinical Protocol for Primary, Secondary (Specialized) and Tertiary (Highly Specialized) Medical Care for Adults with Tuberculosis. 04 September 2014. http://moz.gov.ua/docfiles/dn_20140904_0620_dod.pdf. Accessed 23 Nov 2014.
15. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. 2014. Available at: http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf?ua=1&ua=1. Accessed 15 Nov 2015.
16. Khaliaukin A, Kumar AM, Skrahina A, Hurevich H, Rusovich V, Gadoev J, et al. Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus. Public Health Action. 2014;4Suppl 2:24-8.
17. Dolgusev O, Obevzenco N, Padalco O, Pankrushev S, Ramsay A, Van den Bergh R, et al. Pattern of primary tuberculosis drug resistance and associated treatment outcomes in Transnistria, Moldova. Public Health Action. 2014;4 Suppl 2:64-6.
18. Kuksa L, Riekstina V, Leimane V, Ozere I, Skenders G, Van den Bergh R, et al. Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes. Public Health Action. 2014;4 Suppl 2:47-53.
19. Keshavjee S, Gelmanova IY, Farmer PE, Mishustin SP, Strelis AK, Andreev YG, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372(9647):1403-9.
20. Lytvynenko N, Cherenko S, Feschenko Y, Pogrebna M, Senko Y, Barbova A, et al. Management of multi- and extensively drug-resistant tuberculosis in Ukraine: how well are we doing? Public Health Action. 2014;4 Suppl 2:67-72.
21. Gandhi NR, Andrews JR, Brust JC, Montreuil R, Weissman D, Heo M, et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2012;16(1):90-7.
22. Daniels JF, Khogali M, Mohr E, Cox V, Moyo S, Edginton M, et al. Time to ART initiation among patients treated for rifampicin-resistant tuberculosis in Khayelitsha, South Africa: impact on mortality and treatment success. PLoS One. 2015;10(11): 0142873.
23. Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, et al. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014;59(1):9-15.
24. Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, Atwood SS, et al. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013;8: e58664.
25. Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, et al. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013;56(6):770-6.
26. Padayatchi N, Naidu N, Yende-Zuma N, O’Donnell MR, Naidoo K, Augustine S, et al. Implementation and operational research: clinical impact of the Xpert MTB/RIF assay in patients With multidrug-resistant tuberculosis. J Acquir Immune Defic Syndr. 2016;73(1):e1-7.
27. Ciobanu A, Domente L, Soltan V, Bivol S, Severin L, Plesca V, et al. Do incentives improve tuberculosis treatment outcomes in the Republic of Moldova? Public Health Action. 2014;4 Suppl 2:59-63.
28. Gelmanova IY, Taran DV, Mishustin SP, Golubkov AA, Solovyova AV, Keshavjee S. ‘Sputnik’: a programmatic approach to improve tuberculosis treatment adherence and outcome among defaulters. Int J Tuberc Lung Dis. 2011;15(10):1373-9.
29. Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(3):299-307.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Ways to optimize radiation therapy of lung cancer patients (RUS)O. Y. StoliarovaNational Cancer Institute, Kyiv, Ukraine |
---|
Keywords: lungs, cancer, radiation therapy, optimization.
List of references:
1. Ceniceros L, Aristu J, Castanon E, Rolfo C, Legaspi J, Olarte A et al. Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients. Clin Transl Oncol. 2015;55(8):213-9. doi: 10.1186/s13014-015-0417-5.
2. Chen X, Kong X, Zhang Z, Chen W, Chen J, Li H et al. Alpha‑2-macroglobulin as a radioprotective agent: a review. Chin J Cancer Res. 2014;26 (5):611-21. doi: 10.3978/j.issn.1000-9604.2014.09.04.
3. Datta NR, Samiei M, Bodis S. Radiotherapy infrastructure and human resources in Europe - present status and its implications for 2020. Eur J Cancer. 2014;50(15):2735-43. doi: 10.1089/tmj.2014.0154.
4. Fan X, Jia C, Yang J, Li G, Mao H, Jin Q, Zhao J. A microfluidic chip integrated with a high-density PDMS-based microfiltration membrane for rapid isolation and detection of circulating tumor cells. Biosens Bioelectron. 2015;71(15):380-6. doi: 10.1016/j.bios.2015.04.080.
5. Farr KP, Muller DS, Khalil AA, Kramer S, Morsing A, Grau C. Loss of lung function after chemo-radiotherapy for NSCLC measured by perfusion SPECT/CT: Correlation with radiation dose and clinical morbidity. Acta Oncol. 2015;23(7):1-5. doi: 10.3109/0284186X.2015.1061695.
6. Gràdalska-Lampart M, Karczmarek-Borowska B, Radziszewska AU. Lung cancer in Podkarpackie region in the years 2002-2011. Pneumonol Alergol Pol. 2015;83 (2):109-19. doi: 10.5603/PiAP.2015.0018.
7. Khalil AA, Hoffmann L, Moeller DS, Farr KP, Knap MM. New dose constraint reduces radiation-induced fatal pneumonitis in locally advanced non-small cell lung cancer patients treated with intensity-modulated radiotherapy. Acta Oncol. 2015;22(7):1-7. doi: 10.3109/0284186X.2015.1061216.
8. Kong FM, Wang S. Nondosimetric risk factors for radiation-induced lung toxicity. Semin Radiat Oncol. 2015;25(2): 100-9. doi: 10.1016/j.semradonc.2014.12.003.
9. Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15 (6):347-60. doi: 10.1038/nrc3925.
10. Lian C, Li H, Denoeux T, Chen H, Robinson C, Vera P, Ruan S. MO-AB-BRA‑10: Cancer therapy outcome prediction based on dempster-shafer theory and pet imaging. Med Phys. 2015;42(6):3549. doi: 10.1109/TBME.2017.2688453.
11. Neal JW, Gainor JF, Shaw AT. Developing biomarker-specific ànd points in lung cancer clinical trials. Nat Rev Clin Oncol. 2015;12(3):135-46. doi: 10.1038/nrclinonc.2014.222.
12. Oh JH, Craft JM, Townsend R. A bioinformatics approach for biomarker identification in radiation-induced lung inflammation from limited proteomics data. J Proteome Res. 2011;10(3):1406-15. doi: 10.1021/pr101226q.
13. Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122(12):2011-8. doi: 10.1182/blood‑2013-04-460147.
14. Page BR, Hudson AD, Brown DW, Shulman AC, Abdel-Wahab M, Fisher BJ, Patel S. Cobalt, linac, or other: what is the best solution for radiation therapy in developing countries? Int J Radiat Oncol Biol Phys. 2014;89(3):476-80. doi: 10.1016/j.ijrobp.2013.12.022.
15. Pollock S, O’Brien R, Makhija K, Hegi-Johnson F, Ludbrook J, Rezo A et al. Audiovisual biofeedback breathing guidance for lung cancer patients receiving radiotherapy: a multi-institutional phase II randomised clinical trial. BMC Cancer. 2015;18(15):526-36. doi: 10.1186/s12885-015-1483-7.
16. Ricardi U, Badellino S, Filippi AR. Stereotactic radiotherapy for early stage non-small cell lung cancer. Radiat Oncol J. 2015;33(2):57-65. doi: 10.3857/roj.2015.33.2.57.
17. Safi S, Rauch G, Op den Winkel J, Kunz J, Schneider T, Bischof M et al. Sublobar resection, radiofrequency ablation or radiotherapy in stage i non-small cell lung cancer. Respiration. 2015;89(6):550-7. doi: 10.1159/000381555.
18. Shen B, Zhao K, Ma S, Yuan D, Bai Y. Topotecan-loaded mesoporous silica nanoparticles for reversing multi-drug resistance by synergetic chemoradiotherapy. Chem Asian J. 2015;10(2):344-8. doi: 10.1002/asia.201403117.
19. Wallerek S, Sorensen JB. Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I—$ 5IIA. Eur Respir Rev. 2015;24(136):340-55. doi: 10.1183/16000617.00005814.
20. Xie D, Marks R, Zhang M, Jiang G, Jatoi A, Garces YI et al. Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers. J Thorac Oncol. 2015;10(8):1213-20. doi: 10.1097/JTO.0000000000000585.
21. Zhang H, Xia H, Zhang L, Zhang B, Yue D, Wang C. Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer. Am J Surg. 2015;11(1):150-60. doi: 10.1016/j.amjsurg.2015.03.022.
To download
full version need login
Original language: Russian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Some questions of the epidemic of «family» tuberculosis (UKR)I. D. Duzhiy, L. A. Bondarenko, V. O. OleshchenkoSumy State University, Sumy, Ukraine |
---|
Keywords: «family» tuberculosis, sources of «family» tuberculosis.
List of references:
1. Bialyk IB. The efficacy and tolerance of the intensive anti-tuberculosis treatment at multidrug-resistant destructive pulmonary tuberculosis patients with simultaneous and equable during the day administration of antituberculous drugs. Tuberculosis, lung diseases, HIV infection. 2014;3(18):11-15 (in Ukr).
2. Duzhyy ID. Khirurhiya tuberkul³ozu lehen³ ta plevry. K: Zdorovya. Sumy VAT «SOD»; Vydavnytstvo «Kozatskyy val»;2003:360 (in Ukr).
3. Lytvynenko NA, Feshchenko Yu I, Pogrebna MV åt al. Efficacy of treatment MDR and XDR tuberculosis: the main reasons for poor results. Tuberculosis, lung diseases, HIV infection. 2016;2(25):22-29 (in Ukr).
4. Litvinuk OP, Zaykov SV, Zakharchenko OO, Klimenko TI. The incidence of tuberculosis health workers of Vinnytsya region. Tuberculosis, lung diseases, HIV infection. 2015;2(21):101-105 (in Ukr).
5. Nakaz Ministerstva okhorony zdorov»ya Ukrayiny vid 4 veresnya 2014 roku N 620 «Pro zatverdzhennya ta vprovadzhennya medyko-tekhnolohichnykh dokumentiv zi standartyzatsiyi medychnoyi dopomohy pry tuberkulozi» (in Ukr).
6. Petrenko VI, Panasyuk OV, Radysh GV åt al. Comparative results of treatment of patients with TB (unspecified localization, ryfampicinresistant of lungs, multiresistant of lungs, milliar and multiresistant of nervous system) combined with HIV infection. Tuberculosis, lung diseases, HIV infection. 2017;1(28):21-26 (in Ukr).
7. Petrenko VI, Proziuk RG. The problem of tuberculosis in Ukraine. Tuberculosis, lung diseases, HIV infection. 2015;2(21):16-29 (in Ukr).
8. Pylypchuk NS, Podlesn³kh HA, PylypchukVN. Oshybky v dyahnostyke zabolevanyy lehkykh. K.: Zdorovya, 1993:247 (in Rus).
9. Suprun U. Kontseptsiya zahalnoderzhavnoyi tsilovoyi sotsialnoyi prohramy protydiyi zakhvoryuvannyu na tuberkuloz na 2017-2021 roky. Tuberkuloz, lehenevi khvoroby, VIL-infektsiyi. 2017;1:5-11 (in Ukr).
10. Feshchenko Yu I, Melnyk VM, Turchenko LV, Lirnyk SV. Tuberculosis: organization of diagnosis, treatment, prevention and control of mortality. Ê.: Zdorovya, 2010:448 (in Ukr).
11. Khomenko AG, Chukanov VI, Mishin VYu. Detection, diagnosis and chemotherapy of tuberculosis of respiratory organs in modern epidemiological conditions. Methodical manual for doctors. Moscow, 2000:36 (in Rus).
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Damage of liver function in newly diagnosed patients with multidrug-resistant pulmonary tuberculosis (UKR)L.A. Hryshchuk1, O.M. Okusok21 I.Ya. Horbachevsky Ternopil State Medical University, Ministry of Healthcare of Ukraine, Ternopil, Ukraine |
---|
Keywords: multidrug-resistant pulmonary tuberculosis, functional disorders of the liver, biochemical markers.
List of references:
1. «Analiz prohalyn u likuvanni tuberkul’ozu» final’nyy zvit proektu GRANT-03-OR [Elektronnyy resurs]. - Rezhym dostupu: http://pdf.usaid.gov/pdf_docs/PA00MHB8.pdf (in Ukr).
2. Balasanyants GS, Sukhanov DS. Pobochnyye deystviya protivotuberkuleznykh preparatov i metody ikh ustraneniya. Sankt-Peterburg: Taktik-Studio, 2011:88 (in Rus).
3. Volf SB. Adverse reactions to tuberculosis chemotherapy.
J Grodno State Medical University. 2016;3:141-146 (in Rus).
4. Galan IO, Pavlenko EN, Potaychuk VI, Zdoryk IF. Influence of antituberculosis therapy on some indices of protein metabolism and hepatobilliary system in patients with newly diagnosed lung tuberculosis. Ukr Pulmonol J. 2008;3:70-72 (in Ukr).
5. Zozuliak VI, Zozuliak NV, Pylypenko II. Biochemical features of liver’s difunction in treatment of patients with destructive pulmonary tuberculosis. Tuberculosis, pulmonary diseases, HIV-infection. 2015;2(21):85-89 (in Ukr).
6. Koroliova MV. Pharmaco-epidemiological, clinical and laboratory characteristics of drug-induced liver injury in tuberculosis / J Infectiol. 2015;7(4):44-50 (in Rus).
7. Okusok OM, Hryshchuk LA. Impact of toxic hepatitis on treatment efficiency of drug-resistant pulmonary tuberculosis. Inf Dis. 2016;4:77-81. Doi 10.11603 / 1681-2727.2016.4.7220 (in Ukr).
8. Perelik zakhvoryuvan’ pechinky, yikh symptomy ta diahnostyka [Elektronnyy resurs]. Rezhym dostupu: http://medprice.com.ua/ukr/articles/perelik-zahvoryuvan-pechinki-yih-simptomi-ta-diagnostika-4708.html (in Ukr).
9. Petrenko VI, Proziuk RG. The problem of tuberculosis in Ukraine. Tuberculosis, pulmonary diseases, HIV infection. 2015;2(21):16-29 (in Ukr).
10. Lyashenko OO, Poteyko PI, Lebid LV et al. A method for diagnosing the possible course of pulmonary tuberculosis. Patent number: 96483. Published: Feb 10, 2015. [Electronic resource]. Mode of access: http://uapatents.com/7-96483-sposib-diagnostiki-mozhlivogo-perebigu tuberkulozu-legeniv.html (in Ukr).
11. Raznatovs’ka OM. Otsinka biokhimichnykh pokaznykiv ta aktyvnosti zapal’noho protsesu u khvorykh na khimiorezystentnyy tuberkul’oz lehen’. Ukrayinskyy zhurnal klinichnoyi ta laboratornoyi medytsyny. 2011;6(1):181-184 (in Ukr).
12. Todoriko LD, Petrenko VI, Grishin MM. Resistance of Mycobacterium tuberculosis: myths and reality. Tuberculosis, pulmonary diseases, HIV infection. 2014;1(16):60-67 (in Ukr).
13. Tuberkul’oz v Ukrayini: analitychno-statystychnyy dovidnyk./ MOZ Ukrayiny. DU «Ukrayins’kyy tsentr kontrolyu za sotsial’no-nebezpechnymy khvorobamy MOZ Ukrayiny».Kyyiv: Blank-Pres, 2015. [Elektronnyy resurs]. Rezhym dostupu: http://www.slideshare.net/Ukraine_CDC/2014-52881494 (in Ukr).
14. Unifikovanyy klinichnyy protokol pervynnoyi, vtorynnoyi (spetsializovanoyi) ta tretynnoyi (vysokospetsializovanoyi) medychnoyi dopomohy doroslym. Tuberkul’oz. [Nakaz MOZ Ukrayiny vid 04.09.2014 r. ¹ 620].K.: Ministerstvo okhorony zdorov’ya, 2014:128 (in Ukr).
15. Feshchenko YuI, Lytvynenko NA, Pogrebna MV et al. Efficacy of treatment MDR and XDR tuberculosis: the main reasons for poor results. Tuberculosis, pulmonary diseases, HIV-infection. 2016;2(25):22-29 (in Ukr).
16. Feshchenko YuI, Cherenko SO, Matveeva OV et al. Adverse reaktions of anti-tuberkulosis drugs in treatment of patients with tuberculosis. Tuberculosis, pulmonary diseases, HIV-infection. 2014;4(19):13-20.
7. Baghaei P, Tabarsi P, Chitsaz E et al. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Am J Ther. 2010;17(1):17-22.
18. Keshavjee S, Gelmanova IY, Shin SS et al. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Int J Tuberc Lung Dis. 2012;16(5):596-603. Doi: 10.5588/ijtld.11.0591.
19. Lee SS, Lee CM, Kim TH et al. Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis.2016;20(6):800-805. Doi: 10.5588/ijtld.15.0668.
20. Hsu HL, Bai KJ, Chiang YC et al. Hepatitis associated with prothionamide for treatment of multidrug-resistant tuberculosis. J Formos Med Assoc. 2010;109(12):923-927. Doi: 10.1016/S0929-6646(10)60141-6.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Etiological structure and trends of dynamics of pulmonary syndrome dissemination among patients with physio-pulmonological profile (UKR)N. S. Opanasenko, M. I. Kalenichenko, Î. V. Tereshkovich, V. I. Borisova, R. S. Demus, O. K. OremskaSI «National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of NAMS of Ukraine», Kyiv, Ukraine |
---|
Keywords: pulmonary dissemination, morbidity structure, morbidity dynamics.
List of references:
1. Havrysiuk VK et al. Idiopathic pulmonary fibrosis: clinical picture, diagnosis, treatment. Ukr Pulmonol J. 2012;3:55-59. (in Rus.).
2. Havrysiuk VK et al. Essays on clinical pulmonology. K: Veles;2016:336. (in Rus.).
3. Havrysiuk VK. Rare interstitial lung diseases. K.: Veles; 2012:148. (in Rus.).
4. Ilkovych MM. Disseminated lung diseases. K.: HEOTAR-Medya; 2011:480. (in Rus.).
5. Feshchenko YuI, Melnyk VM, Ilnytskyi IH. Diseases of the respiratory system. Kyiv-Lviv; 2008:495. (in Ukr.).
6. Feshchenko YuI et al. Idiopathic interstitial pneumonia: clinic, diagnosis, treatment (draft national agreement). Ukr Pulmonol J. 2008;3(Dodatok):38-46. (in Ukr.).
7. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192:e3–e19.
8. Navaratnam V et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66(6):462-467.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Comparative analysis of efficiency of isoniazidmonoresistant tuberculosis treated with different drug regimens (RUS)O.Î. Hovardîvska1, O. S. Shevchenko1, T. V. Sencheva2, T. F. Kovaleva21 Kharkiv National Medical University, Kharkiv, Ukraine |
---|
Keywords: tuberculosis, isoniazidmonoresistant TB, treatment outcomes, individual drug regimen.
List of references:
1. Nakaz MOZ Ukrainy N 1091 vid 21.12.2012 r. «Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry tuberkulozi».
2. Nakaz MOZ Ukrainy N 600 vid 22.10.2008 h. «Pro zatverdzhennia standartu nadannia medychnoi dopomohy khvorym na khimiorezystentnyi tuberkuloz».
3. Nakaz MOZ Ukrainy N 620 vid 04.09.2014 r. «Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy doroslym».
4. Nizova NM ta in. Tuberkuloz v Ukrayini [Tekst]: analityko-statystychnyy dovidnyk. Kyiv: Blank-Pres, 2015:142.
5. Petrenko VI. Do mizhnarodnoho dnya borotby z tuberkulozom: Okhopyty try milyony: vyavyty, likuvaty, vylikuvaty tuberkuloz" Tuberkuloz, lehenevi khvoroby, VIL-infektsiya. 2014;1:5-7.
6. Feshchenko YuI, Melnyk VM, Turchenko LV. A fight with tubrculosis in Ukraine: view to a problem. Ukr Pulmonol J. 2016;3:5-10.
7. Shevchenko ÎS, Hovardîvska OA. Drug resistant tuberculosis: the dynamic of epidemiological indicators in groups of patients with new and reccured cases. Tuberkuloz, lehenevi khvoroby, VIL-infektsiya. 2016;4:98-102.
8. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva: World Health Organization; 2008:77.
9. WHO Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014:100.
To download
full version need login
Original language: Russian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 The mechanism of oxygen exchange in living nature and its disturbance in multidrug-resistant tuberculosis patients (UKR)S. I. Kornaha, I. T. Pyatnochka, N. V. ThorókI.Ya. Horbachevsky Ternopil State Medical University, Ministry of Healthcare of Ukraine, Ternopil, Ukraine |
---|
Keywords: multidrug-resistant, infiltrative, disseminated tuberculosis, oxygen saturation of blood.
List of references:
1. Gavrysiuk VK. Respiratory failure: mechanisms of development,evaluation methods, oxygen therapy (Ukr). Ukr pulmonol J [Ukrainian Pulmonology Journal] (Ukr). 2016;4;56-58.
2. Opimakh SG. Evaluation of oxygen gas exchange in chronic obstructive pulmonary disease patients (Ukr). Astma ta alergiya [Asthma and allergy] (Ukr). 2013;4;34-39.
3. Pyatnochka IT, Kornaha SI, Thorók NV. Blood oxygen saturation at different forms of lung tuberculosis depending on the various factors (Ukr). Visnyk naukovych doslidzhen'. 2013;1;12-14.
4. WHO manual on pulseoximetry. World Health Organization; 2009:23.
5. Safonov VA. Dyhanie - etoxhyzn' (Rus.). M. Znaniye; 1982:64.
6. Fizicheskaya kul'tura, zdravoochraneniye I obrazovaniye. Materialy X mezhdunarodnoyi nauchno-prakticheskoiy konferenzcii, posvyashchonnoyi pamyati VS Pirusscogo. Tomsk, 17 noyabrya 2016. Podred. prof. VGShil'ko. Tomsk; 2016:376.
7. Frayt V, Frayt O, Frayt YU. Legeneve krovopostachannya, gipertenziya i tuberkul'oz. Drogobich: Vidrodzhennya; 2001:291.
8. Global initiative for chronic obstructive lung disease revised 2011[Text] / GOLD executive committee, GOLD-science committee; 2011:90.
9. Ocenaczynnościpłuc w chorobachukładuoddechowego / Red. Janusz Kowalski, Antoni Koziorowski, Leszek Radwan, Małgorzata Bartosiewicz et al. Warszawa: Borgis;2004:392.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Dynamics of immunity changes in patients with multi-resistant pulmonary tuberculosis during the intensive phase of treatment (UKR)I. L. Platonova1, M. I. Sakhelashvili2, Î. A. Tkach1, N. E. Lapovec’1, G. D. Shtybel2, O. V. Omelyan3, R. M. Tupychak3, M. K. Novosad3, A. J. Szczåsny3 2 Lviv National Medical Universitynamed after Danylî Galitsky, Lviv, Ukraine 3 PU «Lviv Regional pulmonologyclinicaldiagnostic and treatment center», Lviv, Ukraine |
---|
Keywords: multi drug resistant tuberculosis, changes in immune system, chemotherapy.
List of references:
1. Lytvynenko NA. Faktory ryzyku shchodo vynyknennya rozshyrenoyi ta prerozshyrenoyi rezystentnosti MBT sered patsiyentiv z mul'tyrezystentnym tuberkul'ozom. Suchasni med. tekhnol. 2014;2:36-42.
2. Mel'nyk VM, Novozhylova IO, Matusevych VH. Khimiorezys tentnyy tuberkul'oz: stan problemy v Ukrayini. Ukr med chas. 2013;6:26-28.
3. Mordyk AV, Batishcheva TL, Bryukhanova NS, Puzyreva LV. Vliyaniye immunologicheskikh narusheniy na iskhod vpervyye vyyavlennogo infil'trativnogo tuberkuleza u sotsial'no sokhrannykh patsiyentov. Infektsiya i immunitet. 2014;4(4):353-358.
4. Petrenko VI, Dolynska MH. Ob’iednuimosia, shchob poklasty krai tuberkulozu!. Tuberkuloz, lehenevi khvoroby, VIL-infektsiia. 2016;1:5-6.
5. Tuberkuloz v Ukraini: analitychno-statystychnyi dovidnyk. Tuberkuloz, lehenevi khvoroby, MOZ Ukrainy, DU «Ukrainskyi tsentr kontroliu za sotsialno-nebezpechnymy khvorobamy MOZ Ukrainy», Derzhavnyi zaklad «Tsentr medychnoi statystyky MOZ Ukrainy»; uklad. Nizova NM, Pavlova OV, Shcherbinska AM ta in. K.: Blank-Pres; 2015:116
6. Feshchenko YuI, Melnyk VM, Zaikov SV ta in. Osoblyvosti suchasnoi sytuatsii z tuberkulozu v Ukraini. Ukr pulmonol. zhurn. 2016;1:5-9.
7. Feshchenko YuI, Melnyk VM, Matusevych VH, Novozhylova IO. Naukovi pidkhody do vyrishennia problem tuberkulozu. Ukr pulmonol zhurn. 2013;2:5-14
8. Feshchenko YuI, Melnyk VM, Matusevych VH ta in. Orhanizatsiini pidkhody do vyiavlennia i likuvannia khvorykh na tuberkuloz iz rezystentnistiu do antymikobakterialnykh preparativ (metodychnyi posibnyk). Orhanizatsiini pidkhody do vyyavlennia i likuvannia khvorykh. [Elektronnyi resurs]. Rezhym dostupu: http://ifp.pulm/ftp1/metoddoc/posibnyk_2_2013.
9. Chernushenko YeF, Panasyukova AR. Immunologicheskiye me -khanizmy progressirovaniya tuberkuleza. Ekolohichni problemy u ftyziatrii i pulmonolohii: mater. nauk.-prakt.konf. K;2004:222-225.
10. Aleman M, Garcia A, Saab M, et al. Mycobacterium tuberculosis - inducet activation accelerates apoptosis in peripheral blood neutrophils from patients with active tuberculosis. Am J Respir Cell Mol Biol. 2002;27:583-592.
11. Anibarro L, et al. Tretment completion in latent tuberculosis infectionat specialist tuberculosis unitsin Spain. Int J Tuber Lung Dis. 2010;14(6):701-707.
12. Ciobanu S, Lesnic E, Todoriko L, Haidarli I, Tudos. Predictive exogenous conditions for tuberculosis treatment default. Tuberkuloz, lehenevi khvoroby, VIL-infektsiia. 2015;3(22):35-38.
13. Flynn JL, Chan J. Immune evasion by Mycobacterium tuberculosis: living with the Enemy. Curr Opin Immunol Cell Mol Biol. 2003;15:450-455.
14. Lunnroth K, et. al. Tuberculosis control andelimination 2010-50: cure, careandsocial development. Lancet. 2010;375:1814-1829.
15. Wahab F, et al. Risk factors for multi-drug resistant tuberculosis in patients at tertiary care hospital, Peshawar. J Coll Physicians Surg Pak. 2009;19(3):162-164.
16. World Health Organization. Global tuberculosis report 2015. Geneva: WNO, 2015.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Regulatory management for preventive regimen by dental care for persons living with HIV/AIDS (UKR)V.I. Shatylo1, J.Ya. Halinskyi2, V.M. Kosenko11 MHEI «Zhytomyr Nursing Institute» of Zhytomyr Regional Council, Zhytomyr, Ukraine |
---|
Keywords: HIV-infected, dental care, sanitary and anti-epidemic regime.
List of references:
1. Borysenko AV, Antonenko MIu, Lynovytsk LVa ta in. Stomatolohichni zakhvoriuvannia: terapevtychna stomatolohiia: pidruchnyk. Za red. AV Borysenka. K. VSV «Medytsyna», 2017:664.
2. Borovskyi E.V., Mashkylleison A.I. Zabolevanyia slyzystoi obolochky polosty rta y hub. M.; MEDpress, 2001:320.
3. Danylevskyi NF, Borysenko AV, Antonenko MIu y dr. Terapevtycheskaia stomatolohyia. Zabolevanyia parodonta. K. Medytsyna, 2013;4:632.
4. Nakaz N 148 vid 17.03.2015 «Pro zatverdzhennia Poriadku pidtverdzhennia zviazku zarazhennia VIL-infektsiieiu z vykonanniam pratsivnykom svoikh profesiinykh oboviazkiv». [Elektronnyi resurs]. Rezhym dostupu: http://search.ligazakon.ua/l_doc2.nsf/link1/RE 26822.html. (data zvernennia 21.10.2016).
5. Nakaz N 236 vid 4.04.2012 «Pro orhanizatsiiu kontroliu ta profilaktyky pisliaoperatsiinykh hniino-zapalnykh infektsii, sprychynenykh mikroorhanizmamy, rezystentnymy do dii antymikrobnykh preparativ». [Elektronnyi resurs]. Rezhym dostupu: http://search.ligazakon.ua/l_doc2.nsf/link1/RE 21224.html. (data zvernennia 27.09.2016).
6. Nakaz N 325 vid 8.06.2015 «Pro zatverdzhennia Derzhavnykh sanitarno-protyepidemichnykh pravyl i norm shchodo povodzhennia z medychnymy vidkhodamy». [Elektronnyi resurs]. Rezhym dostupu: http://search.ligazakon.ua/l_doc2.nsf/link1/RE 27404.html. (data zvernennia5.10.2016).
7. Nakaz N 410 vid 22.05.2013 «Pro zatverdzhennia form oblikovoi dokumentatsii ta zvitnosti stosovno reiestratsii vypadkiv kontaktu osib z kroviu chy biolohichnymy materialamy liudyny, zabrudnenymy nymy instrumentariiem, obladnanniam chy predmetamy, provedennia postkontaktnoi profilaktyky VIL-infektsii ta instruktsii shchodo yikh zapovnennia». [Elektronnyi resurs]. Rezhym dostupu: http://search.ligazakon.ua/l_doc2.nsf/link1/RE 23434.html. — (data zvernennia 10.10.2016).
8. Nakaz N 552 vid 11.08.2014 «Pro zatverdzhennia Derzhavnykh sanitarnykh norm ta pravyl «Dezinfektsiia, peredsterylizatsiine ochyshchennia ta sterylizatsiia medychnykh vyrobiv v zakladakh okhorony zdorovia». [Elektronnyi resurs]. Rezhym dostupu: http://www.infectioncontrol.org.ua/wp content/docs/Nakaz.552_11.08.2014_sanpin_ster.pdf. (data zvernennia 18.09.2016).
9. Nakaz N 955 vid 5.11.2013 «Poriadok provedennia ekstreno postkontaktnoii profilaktyky VIL-infektsii u pratsivnykiv pry vykonanni profesiinykh oboviazkiv». [Elektronnyi resurs].-Rezhym dostupu: http://search.ligazakon.ua/l_doc2.nsf/link1/RE 24512.html. (data zvernennia 14.09.2016).
10. Nikolishyn AK, Zhdan VM, Borysenko AV ta in. Terapevtychna stomatolohiia. Zakhvoriuvannia slyzovoi obolonky porozhnyny rota. Vinnytsia, Nova Knyha, 2012:680.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Gender characteristics of multidrug-resistant pulmonary tuberculosis (UKR)I.A. Ovcharenko, O.S. ShevchenkoKharkiv National Medical University, Kharkiv, Ukraine |
---|
Keywords: gender, multidrug-resistant tuberculosis, treatment effectiveness, destruction, bacterial excretion.
List of references:
1. WHO report on the global fight against TB by 2016. http://www.who.int/tb/publications/global_report/gtbr2016_executive_summary_ru.pdf? ua=1
2. Koretskaya NM, Narkevich ÀÀ, Narkevich ÀN. Gender features of newly diagnosed infiltrative pulmonary tuberculosis. Pul’monologiya;1:77-80.
3. Order of Ukrainian Ministry of Health N 600 of 22.10.2008 “On approval of the standard of care for patients with chemoresistant tuberculosis”. Ukrainian Ministry of Health. Kyiv, 2008:105.
4. Order of Ukrainian Ministry of Health N 1091 of 21.12.2012 «On approval and introduction of medical and technological documents for standardization of care in tuberculosis». Ukrainian Ministry of Health. Kyiv, 2012:172.
5. Order of Ukrainian Ministry of Health ¹ 620 of 14.09.2008 «On approval of the standard of care for patients with himiorezystentnyy tuberculosis». Ukrainian Ministry of Health. Kyiv, 2014;105.
6. Petrenko VI To the World TB day: « Reach the 3 million: find, treat, cure TB»// Tuberculosis, Lung diseases, HIV-infectin. Kyiv;2014:5-7.
7. Tuberculosis and Gender aspects. http://www.euro.who.int/__data/assets/pdf_file/0005/69017/fs05R_TBgender.pdf.
8. Feshchenko YuI, Melnyk VM, Matusevych VH, Novozhylova IO, YukhymetsVO, LynnykMI. Basic principles of medical care for patients with tuberculosis (guidance on organizational and technical work). Kyiv;2012:156.
9. What is a gender-sensitive approach? The German Initiative BACKUP / German Society for International Cooperation (GIZ). GmbH. Bonn. Germany; 2013:7.
10. World Health Organization. WHO Treatment guidelines for drug-resistant tuberculosis — 2016 update / [Text]. WHO: Geneva;2016:60.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Immunopathogenesis of resistant tuberculosis from the positions of the today (UKR)L. D. TodorikoHSEI Ukraine «Bukovinian State Medical University», Chernivtsi, Ukraine |
---|
Keywords: immunopathogenesis, cellular immunity, tuberculosis, chemoresistance, cytokines, apoptosis.
List of references:
1. Abdulaev R, Kaminskaya G, Komissarova O. Shifts in the system of hemostasis — a component of the systemic inflammatory response in pulmonary tuberculosis. Vrach. 2012;2:7-11.
2. Antonenko PB, Kresyuk VY, Bazhora YuI et al. The genotyping of micobacterium tuberculosis at six loci. Ukr Pulmon J. 2010;3:15-18.
3. Varchenko Yu A. Influence of interferon on the dynamics of closure of decomposition cavities in patients with infiltrative first-time diagnosed pulmonary tuberculosis. Tuberculosis, pulmonary diseases, HIV infection. 2013;1:26-29.
4. Bazhora YuM et al. Molekulyarno-geneticheskiye mekhanizmy tuberkuleznoy infektsi. Odessa: Odesskiy gosudarstvennyy meduniversitet; 2005:259.
5. Dzyublyk YO. Antibiotic resistance of respiratory pathogens: a review of the results of the SOAR study and the prospects for microbiological monitoring in Ukraine. Ukr Pulmon J. 2010;3:33-35.
6. Kaminskaya GO, Abdulaev RYu, Martynova EV et al.Syndrome of systemic inflammatory response in pulmonary tuberculosis. Tub Lung Dis. 2009;11:40-48.
7. Karachunsky MA. Molecular epidemiology of tuberculosis. Probl Tub Lung Dis. 2007;4:3-7.
8. Liadova IV, Gergert VA. Reaction of T-cell immunity in tuberculosis: experimental and clinical studies. Tub Lung Dis. 2009;11:9-18.
9. Melnik VM, Prikhodko AM, Arefeva LV. History of the emergence and development of chemo-resistant tuberculosis. Ukr Pulmon J. 2012;2:59-61.
10. Novitsky VV, Voronkova OV, Urazova OI et al. On the pathology of immunity in pulmonary tuberculosis. Pathological Physiology and Experimental Therapy. 2008;1:15-18.
11. Todoriko LD, Petrenko VI, Grishin MM. Resistance of Mycobacterium tuberculosis — myths and realities. Tub Pulmonary Dis HIV infection. 2014;1:60-67.
12. Urazova OI, Novitsky VV, Strelis AK et al. Apoptosis of blood lymphocytes in patients with pulmonary tuberculosis. Proceedings of the All-Russian Scientific and Practical Conference with International Participation: Questions of the pathogenesis of typical pathological processes. Novosibirsk, 2009:392-396.
13. Feshchenko YuI, Gumenyuk MI, Denisov OS. Antibiotic resistance of microorganisms: the state of the problem and the ways of its solution. Ukr Chemotherapeutic J. 2011;1-2:4-10.
14. Todoriko LD. Features of evolution of immunopathogenesis of drug-resistant tuberculosis. Clin Immunol Allergol Infectol. 2014;3:16-20.
15. Feshchenko YuI, Melnik VM, Turchinov LV. A look at the problem of fighting tuberculosis in Ukraine. Ukr Pulmon J. 2016;3:5-10.
16. Chernousova LN, Andreevskaya SN, Smirnova TG et al. Properties of strains of M. tuberculosis cluster W. Probl Tub Lung Dis. 2008;10:45-49.
17 Filinyuk OV. Faktory riska, assotsiirovannyye s mnozhestvenno lekarstvenno-ustoychivym tuberkulezom / Avtoreferat dissertatsii dok. med. nauk (14.01.16. ftiziatriya). Novosibirsk, 2011:36.
18. Chernushenko YeG, Protsyuk RG. Antituberculous immunity (part I). Ukr Pulmon J. 2010;4:53-58.
19. Actor JK, Hunter R, Jagannath C. Immunopathology oftul culosis. Molecular pathology of lung diseases. New York: Springer New York, 2008:419-428.
20. Becq J, Gutierrez M, Rosas-Magallanes V et al. Contribution of horizontally acquired genomic islands to the evolution of the tubercle bacilli. J Mol Biol Evol. 2007;24:1861-1871.
21. Caws M, Thwaites G, Dunstan S et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog. 2008;4:450-457.
22. Crane M, Iser D, Lewin SR. Human immunodeficiency virus infection and the liver. World J Hepatol. 2012;4(3):91-98.
23. Ejele OA. A comparative study of CD 4 positive lymphocyte count and the ESR of HIV sero-positivc patients at University of Port Harcourt Teaching Hospital. Pmjumu Pioneer Med. J Umuahia. 2012;2(1):13-21.
24. Hanekom M, van der Spuy GD, Streicher E et al. A recently evolved sublineage of the Mycobacterium tuberculosis Beijing strain family is associated with an increased ability to spread and cause disease. J Clin Microbiol. 2007;45:1483-1490.
25. Jonna Idh, Mekidim Mckonnen, Ebba Abate et al. Resistance to First-Line Anti-TB Drugs Is Associated with Reduced Nitric Oxide Susceptibility in Mycobacterium tuberculosis. PLoSOne. 2012;7(6):39891.
26. Kleinnijenhuis J, Oosting M, Joosten LA et al. Innate Immune Recognition of Mycobacterium tuberculosis. Clin Dev Immunol. 2011: [Ýëåêòðîííûé pecypc]. Ðåæèì äîñòóïà ê äîêóìåíòó: http:. www.ncbi.nlm.nih.gov/pmc/articles/ PMC 3095423.
27. Kruuner A, Yates MD, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol. 2006;44:811-818.
28. Liu X, Gutacker MM, Musser JM et al. Evidence for recombination in Mycobacterium tuberculosis. J Bacteriol. 2006;188:8169-8177.
29. Miller TI. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med. 2012;5:264-275.
30. Mi-Sun Koo, Subbian S, Kaplan G. Strain specific transcriptional response in Mycobacterium tuberculosis infected macrophages. Cell Communication and Signaling. 2012;10:2.
31. Moreland NJ, Charlier C, Dingley AJ et al. Making sense of a missense nutation: characterization of MutT2, a Nudix hydrolase from Mycobacterium tuberculosis, and the G58R mutant encoded in W-Beijing strains of M. Tuberculosis. Biochemistry. 2009;8:699-708.
32. Moreland NJ, Charlier C, Dingley AJ et al. Phylogeny of Mycobacterium tuberculosis Beijing Strains Constructed from Polymorphisms in Genes Involved in DNA Replication. Recombination and Repair. PLoS One. 2011;6(1): [Ýëåêòðîííûé ðåñóðñ]. Ðåæèì äîñòóïà ê äîêóìåíòó: http:. www.plosone.org/article/info%3Adoi%2F10.1371 %2 Fjournal. pone.0016020.
33. Novitsky VV, Urazova OI, Voronkova OV et al. The molecular-genetic bases of management of human adaptable blood system reactivity during infection. Internationaler congress Fachmesse: moderne aspekte der prophylaxe, behandlung und rehabilitation, Hannover, 2008:65-66.
34. Parida SK, Kaufmann SH E. Novel tuberculosis vaccines on the horizon. Curr Opin Immunol. 2010;22(3):374-384.
35. Ralph AP, Anstey NM, Kelly PM. Tuberculosis into the 2010-s: Is the glass half full?. CID. 2009;49:574-583.
36. Rocha-Ramirez LM, Estrada-Garcia I, Lopez-Marin LM et al. Mycobacterium tuberculosis lipids regulate cytokines, TLR‑2/4 and MHC class II expression in human macrophages. Tuberculosis. 2008;88:212-220.
37. Thaiss CA, Kaufmann SH E. Toward novel vaccines against tuberculosis: current hopes and obstacles. Yale J Biol Med. 2010;83:209-215.
11. Todoriko LD. Genetic aspects of the formation of drug resistance of Mycobacterium Tuberculosis. 21 century: fundamental science and technology III / Create Space / North Charleston, SC, USA. 2014. Vol.1:52-54.
39. World Health Organization. Global Tuberculosis Control report. WHO report. 2016. Geneva, Switzerland:273.
To download
full version need login
Original language: Ukrainian
|
Notice: Undefined index: pict in /home/vitapol/tubvil.vitapol.com.ua/en/svizhij_nomer.php on line 74 Tuberculosis morbidity of medical workers (UKR)I. D. Duzhiy, L.A. Bondarenko, G. P. Oleshchenko, V. O. OleshchenkoSumy State University, Sumy, Ukraine |
---|
Keywords: tuberculosis, health workers, morbidity.
List of references:
1. Vaganova US.Tuberculosis case rate at workers of medical institutions (Rus). Meditsina i obrazovanie v Sibiri (Rus). 2015;2:27-34.
2. Kundiev YI, Varyvonchyk DV, Nahorna ÀÌ, Sokolova ÌP. Morbidity of occupational tuberculosis in Ukraine (1993-2008) (Ukr). Ukrayinskyj zhurnal z problem medycyny praci (Ukr). 2010;2:3-8.
3. Litvinuk OP, Zaykov SV, Zakharchenko OO, Klimenko TI. The incidence of tuberculosis health workers of Vinnytsya region (Ukr). Tuberkuloz, legenevi xvoroby, VIL-infekciya (Ukr). 2015;2:101-105.
4. Pustovyy YuG, Dolynska MG, Voloshyna VV, Gritsova NA. Risk factors for tuberculosis: prevalence among patients with new cases (Ukr). Ukrayinskyj pulmonologichnyj zhurnal (Ukr). 2009;1:22-24.
5. Skrahina AM, Hurevich HL, Kalechits AM, Klimuk DA, Dziusmikeyeva MI, Bobrukevich AL, i dr. The prevention of the incidence of tuberculosis among medical profession (Rus). Klinicheskaya infektologiya i parazitologiya (Blr). 2015;3:28-39.
6. Tuberkuloz v Ukrayini: Analitychno-statystychnyj dovidnyk (Ukr). Kyiv; 2016:235.
7. Tuberkuloz v Ukrayini: Analitychno-statystychnyj dovidnyk za 2001-2012 roky (Ukr). Kyiv; 2013:122.
8. Feshñhenko YuI, Melnyk VM, Opanasenko MS. Reorganizaciya, restrukturyzaciya ta reformuvannya protytuberkul`oznoyi sluzhby v Ukrayini (Ukr). Kyiv: Vydavnycztvo Lira-K; 2015:172.
9. Feshñhenko Yu I. Tuberkuloz v Ukrayini yak medyko-socialna i politychna problema (Ukr). Zhurnal Akademiyi medychnyh nauk Ukrayiny (Ukr);11(1):17.
10. Cole E, Cook C. Characterization of infectious aerosols in health care facilities: an aid to effective engineering controls and preventive strategies. Am J Infect Control. 1998;26(4):453-464.
11. World Health Organization (WHO). Global tuberculosis report 2015 (WHO/HTM/TB/2015.22). Geneva: WHO; 2015. Available from: http://www.who.int/tb/publications/global_report/en/.
To download
full version need login
Original language: Ukrainian
¹4(31) // 2017